- Trials with a EudraCT protocol (330)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
330 result(s) found for: Endometrial.
Displaying page 5 of 17.
| EudraCT Number: 2021-002924-18 | Sponsor Protocol Number: CYC065-101 | Start Date*: 2021-10-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Cyclacel Pharmaceuticals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Ly... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Endometrial cancer, Ovarian cancer, Biliary tract cancer, Hepatocellular carcinoma, B-cell lymphoma, T-cell lymphoma, Metastatic colorectal cancer, Breast cancer (metastatic HER-2 refractory, Horm... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-019448-38 | Sponsor Protocol Number: UREP-PREPENDO-2010 | Start Date*: 2010-07-01 |
| Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar) | ||
| Full Title: Ensayo clínico, prospectivo, aleatorizado, comparativo, para determinar la eficacia y seguridad de dos protocolos para preparación endometrial en mujeres subsidiarias de transferencia de embriones. | ||
| Medical condition: Preparación endometrial en mujeres subsdiarias de tranferencia de embriones | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003556-20 | Sponsor Protocol Number: 1806-LIS-044-SD | Start Date*: 2019-06-17 |
| Sponsor Name:INSTITUTO VALENCIANO DE INFERTILIDADE - CLÍNICA DE REPRODUÇÃO ASSISTIDA, LDA | ||
| Full Title: How do different ovarian stimulation protocols affect endometrial receptivity during a fresh in vitro fertilization attempt? | ||
| Medical condition: Women with a clinical indication to undergo Assisted Reproductive Technologies for infertility with a predicted normal response to Ovarian Stimulation and planned for a single blastocyst transfer | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: PT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-001071-37 | Sponsor Protocol Number: LUC19-001 | Start Date*: 2019-08-06 |
| Sponsor Name:Cliniques Universitaires Saint-Luc | ||
| Full Title: Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido | ||
| Medical condition: Patients with confirmed primary endometrioid adenocarcinoma eligible for first line curative surgery | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-010290-21 | Sponsor Protocol Number: UMCNONCO200902 | Start Date*: 2009-05-20 |
| Sponsor Name:University Medical Centre Nijmegen St Radboud | ||
| Full Title: A phase Ib study of combination of temsirolimus (Torisel®) and pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®) in advanced or recurrent breast, endometrial and ovarian cancer | ||
| Medical condition: advanced or therapy refractory breast cancer, endometrial cancer, or ovarian cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-003431-29 | Sponsor Protocol Number: CBGG492A2216 | Start Date*: 2014-05-27 |
| Sponsor Name:Novartis Farma S.p.A. | ||
| Full Title: A multicenter medical safety follow-up study for patients with partial onset seizures who received more than 28 days of total exposure to BGG492 in studies CBGG492A2207 and/or CBGG492A2212. | ||
| Medical condition: Testing for adrenal cortical adenomas in male and female patients Testing for uterine endometrial stromal sarcromas in all female patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-003886-34 | Sponsor Protocol Number: CFEM345ADE08 | Start Date*: 2008-06-16 |
| Sponsor Name:Novartis Pharma GmbH | ||
| Full Title: Phase II study on letrozole in patients with advanced or recurrent hormone receptor positive endometrial cancer. | ||
| Medical condition: endometrial cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-003250-34 | Sponsor Protocol Number: IVI-ERA-2011 | Start Date*: 2011-12-13 | |||||||||||
| Sponsor Name:IVI Madrid | |||||||||||||
| Full Title: Endometrial receptivity with different support protocols for the luteal phase in ovarian stimulation cycles in which final oocyte maturation is carried out with GnRH analogues. Analysis by endometr... | |||||||||||||
| Medical condition: Ovarian Hyperstimulation Syndrome (OHSS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-001289-14 | Sponsor Protocol Number: MIT-Do001-C301 | Start Date*: 2020-02-05 | |||||||||||
| Sponsor Name:Estetra SRL | |||||||||||||
| Full Title: A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comf... | |||||||||||||
| Medical condition: Moderate to Severe Vasomotor Symptoms (VMS) in Postmenopausal Women | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) LT (Completed) CZ (Completed) ES (Completed) IT (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-003298-24 | Sponsor Protocol Number: R4018ONC1721 | Start Date*: 2020-06-11 | ||||||||||||||||
| Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||||||||||||||||||
| Full Title: A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers | ||||||||||||||||||
| Medical condition: Recurrent Ovarian Cancer Recurrent Fallopian Tube Cancer Recurrent Primary Peritoneal Cancer Recurrent Endometrial Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2011-000501-52 | Sponsor Protocol Number: PARAGON2011 | Start Date*: 2011-12-07 | ||||||||||||||||
| Sponsor Name:Greater Glasgow and Clyde [...] | ||||||||||||||||||
| Full Title: PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms | ||||||||||||||||||
| Medical condition: Patients with potentially hormone responsive recurrent or metastatic gynaecological cancers from following subgroups: A - Epithelial ovarian cancer, primary peritoneal cancers and cancers of the fa... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2019-003777-26 | Sponsor Protocol Number: D0817C00098 | Start Date*: 2020-05-27 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||||||||||||||||||||||
| Full Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment | ||||||||||||||||||||||||||||||||||||||
| Medical condition: BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BG (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) DK (Completed) BE (Trial now transitioned) SE (Trial now transitioned) FI (Completed) PT (Trial now transitioned) SI (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-003980-74 | Sponsor Protocol Number: BAY1007626/15731 | Start Date*: 2015-06-17 | |||||||||||
| Sponsor Name:Bayer AG | |||||||||||||
| Full Title: Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626,... | |||||||||||||
| Medical condition: Contraception | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) GB (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003150-40 | Sponsor Protocol Number: MIT-Es0001-C301 | Start Date*: 2016-03-11 | |||||||||||
| Sponsor Name:Estetra SPRL | |||||||||||||
| Full Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone | |||||||||||||
| Medical condition: Contraception | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) SE (Completed) FI (Completed) PL (Completed) DE (Completed) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004989-25 | Sponsor Protocol Number: INCAGN1876-201 | Start Date*: 2017-09-28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Biosciences International Sàrl | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Phase 1: advanced or metastatic cervical cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma, melanoma (mucosal or cutaneous), Merkel cell carcinoma, mesothelioma, MSI-H colorectal... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) BE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-001185-10 | Sponsor Protocol Number: 14I/Prg02 | Start Date*: 2014-09-08 | |||||||||||
| Sponsor Name:IBSA Institut Biochimique SA | |||||||||||||
| Full Title: Effect of a progesterone 25 mg solution (Pleyris, IBSA Farmaceutici Italia, srl) administered by oral route compared to an oral progesterone 200 mg capsule (Prometrium, Rottapharm SpA) on the endom... | |||||||||||||
| Medical condition: hormone replacement therapy of menopause (as progestin therapy in association to estrogen replacement therapy) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-011775-78 | Sponsor Protocol Number: 08GINE1 | Start Date*: 2009-01-20 |
| Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO | ||
| Full Title: Evaluation of efficacy of antibiotic prophylaxis in patients undergoing operative hysteroscopy | ||
| Medical condition: Patients needing operative hysteroscopy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: IT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-003938-41 | Sponsor Protocol Number: IMP 28364 | Start Date*: 2007-09-25 | |||||||||||
| Sponsor Name:Merck Lipha Santé SAS | |||||||||||||
| Full Title: Open label pilot study on gene expression profiling of the endometrial tissue in patients undergoing Assisted Reproductive Technology (ART: only IVF) with GONAL-f. | |||||||||||||
| Medical condition: This study will be conducted in infertile women justifying ART (Assisted Reproductive Technology) treatment (only IVF - In Vitro Fecondation) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000518-40 | Sponsor Protocol Number: RAINBO-MMRd-GREEN-ENGOT-EC14_02 | Start Date*: 2022-01-17 |
| Sponsor Name:Leiden University Medical Center | ||
| Full Title: RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial - | ||
| Medical condition: Endometrial Cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-003879-42 | Sponsor Protocol Number: 2021/ABM/03/00006 | Start Date*: 2023-04-12 | ||||||||||||||||
| Sponsor Name:Medical Univeristy of Bialystok | ||||||||||||||||||
| Full Title: A randomized, controlled, double-blind clinical trial evaluating the effect of METformin treatment on endometrial function in women diagnosed with Idiopathic Infertility | ||||||||||||||||||
| Medical condition: Potential causes of idiopathic infertility include in particular: abnormal function of the endometrium, including implantation disorders and immunological abnormalities, genetic abnormalities and t... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Female | |||||||||||||||||
| Trial protocol: PL (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
